Decode DEB™

IMPORTANT NOTICE: Decode DEB Sponsored Testing Program

Please let this serve as a courtesy notice that GeneDx will no longer be accepting test orders for the Decode DEB Program after November 10, 2023.

While the collaboration with GeneDx will be coming to an end on November 10, 2023, access to no-charge genetic testing for dystrophic epidermolysis bullosa (DEB) will continue to be available through Krystal Biotech.  If you have any questions regarding the continuation of the Decode DEB Program, please reach out to your Krystal Biotech Regional Gene Therapy Consultant, call 1-844-5-KRYSTAL, email decodedeb@krystalbio.com or visit DEBFacts.com.

All GeneDx Genetic Test Reports resulting from test orders submitted via the Decode DEB Program that are received on or before November 10, 2023 will continue to be issued as usual, per the reporting preference(s) listed on the GeneDx Test Requisition Form, and within the normal turnaround time for GeneDx Test Code TL45 (2-3 weeks).  If you should have any questions regarding test orders submitted to GeneDx through the Decode DEB Program, please continue to reach out to the BioPharma team via biopharma@genedx.com.

Testing for any orders submitted via the Decode DEB Program that are received after November 10, 2023 will be placed on hold. Our GeneDx clinical team will reach out to discuss testing options.

We value the trust that you have placed in GeneDx with your patient’s genetic testing over the last several years and we look forward to seeing our relationship continue in other ways.  If you should have any questions regarding other available tests here at GeneDx, please reach out to our Client Support team via support@genedx.com to be connected to your local GeneDx Sales Representative and/or Client Relations Manager.